Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalent (NYSE: CTLT ) stock is getting a boost on Tuesday after the consumer health company reached an agreement with Elliott Investment Management. This has Catalent adding four new directors to its Board while also agreeing to conduct a strategic review.

Catalent (CTLT) Stock Gains on Elliott Deal

Catalent (CTLT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $1.19 per share a year ago.

Catalent (CTLT) Q4 Earnings Miss Estimates

The drug manufacturer expects $4.3 billion to $4.5 billion in fiscal 2024 revenue. Analysts has been forecasting $4.2 billion.

Catalent Issues a Solid Outlook and Makes a Deal With Elliot

Shares of Catalent Inc. CTLT, +1.67% jumped 4.1% in premarket trading Tuesday, after the maker of products used by drug makers and consumer health companies announced an cooperation agreement with activist investor Elliott Investment Management LP, as it will appoint four new independent directors. The appointments include Steven Barg, global head of engagement at Elliott.

Catalent stock jumps after cooperation agreement with activist investor Elliott Investment

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better biopharmaceutical treatments for patients worldwide, today announced several initiatives reflecting its ongoing commitment to strong corporate governance and shareholder value creation. The Nominating and Corporate Governance Committee of the Board has recommended, and the Board has approved, the appointment of four new independent directors: Steven Barg, Frank D'Amelio, Ste.

Catalent Announces Governance Enhancements and New Initiatives to Drive Value

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced preliminary financial results for the fourth quarter of fiscal 2023, which ended June 30, 2023. “We continue to make progress in improving our operational performance and continue to win new business with new and existing customers, including in some of the industry's most exciting areas, leading us on a path toward more sus.

Catalent, Inc. Reports Preliminary Fourth Quarter and Fiscal 2023 Results

Catalent Inc is close to reaching a settlement with Elliott Investment Management that would lead to a shake-up of the U.S. contract drug manufacturer's board of directors after its share price lost half of its value in the last year.

Exclusive: Catalent nears settlement with Elliott for board seats -sources

Catalent's plant in Bloomington, Indiana, will fill injection pens for Novo Nordisk's weight-loss drug Wegovy as part of the two companies' expanded supply agreement, two sources familiar with the matter told Reuters.

Exclusive: Catalent's Indiana plant to make Novo's Wegovy weight-loss drug-sources

Novo Nordisk

Novo Nordisk Chief Executive Lars Fruergaard Jorgensen said on Friday he was confident Catalent would resolves its problems making Novo's hugely-popular weight-loss drug Wegovy as the company scrambles to boost output to meet soaring demand.

Novo Nordisk CEO 'confident' Catalent will overcome Wegovy production problems

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the fourth quarter of fiscal year 2023 ended June 30, 2023, before the market open on Tuesday, August 29, 2023. The Company's management will host a webcast to discuss the results at 8:15 a.m. ET on the same day. Catalent invites all interested parties to listen to the webcast and v.

Catalent, Inc. Announces Fourth Quarter Fiscal Year 2023 Earnings Conference Webcast

Allegiant Travel Company

Dollar Tree

Equities have pulled back from their late July highs, though the Q2 reporting season has been solid. We spot three firms with unusual corporate event activity. A problem child is back at the top of our volatility watch list, while an airline stock appears to see brighter skies ahead. Finally, one retail firm reports results this week, and it has a lot to live up to.

Strong Earnings, Troubled Stocks: 3 Companies That May Light Up Volatility Screens

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Lisa Evoli has been named Senior Vice President & Chief Human Resources Officer, effective immediately. Ms. Evoli joins Catalent from Integra Lifesciences, a global medical technology company based in Princeton, New Jersey. “Lisa is a proven leader with more than 25 years of experience achieving organizational resul.

Catalent Appoints Lisa Evoli Senior Vice President and Chief Human Resources Officer

Carnival

Chipotle

Intel

NVIDIA

Warner Bros Discovery Inc

Zions Bancorp

If you liked how S&P 500 stocks did in the first half, you'll love how the second half is starting. And some individual stocks are on fire.

7 Stocks Turn $10,000 Into $99,506 In 7 Months

Emergent BioSolutions

The U.S. Food and Drug Administration has approved the prescription-free sale of the second opioid overdose reversal drug, its manufacturer Harm Reduction Therapeutics said on Friday.

US FDA approves second over-the-counter opioid overdose reversal drug

The factory that fills the self-injection pens for booming weight-loss drug Wegovy has repeatedly breached U.S. sterile-safety rules in recent years and staff have failed to perform required quality checks, a Reuters review of regulatory documents shows.

Insight: Wegovy weight-loss injection factory plagued by sterile-safety failures

Catalent Inc (NYSE: CTLT) jumped nearly 10% this morning after Elliott Investment Management was reported to have built a sizable stake in the contract drug manufacturer.

Catalent shares jump 10% on Elliott news

Catalent stock moved higher on Thursday on reports that activist investor Elliot Investment Management has taken a significant stake in the company. Shares of the contract drugmaker had added 4% at US$48.16 at noon.

Catalent stock rises on reports Elliot Investment has taken a significant stake

Catalent (NYSE: CTLT ) stock is on the move Thursday as investors react to activist investor Elliott Investment taking a stake in the drug-making company. Specific details of the stake Elliott Investment has taken in Catalent are still unknown.

CTLT Stock Alert: What to Know as Elliott Takes a Stake in Catalent

The activist is pushing for a shake-up of the contract drug manufacturer's board.

Elliott Takes Big Stake in Drugmaker Catalent

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Catalent (CTLT) Up 3.5% Since Last Earnings Report: Can It Continue?

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Catalent, Inc. (“Catalent” and/or “Company”) (NYSE: CTLT) breached their fiduciary duties to Catalent and its shareholders. If you are a Catalent shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982, or jpettigrew@scott-scott.com. Scott+Scott is.

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Catalent, Inc.'s Directors and Officers for Breach of Fiduciary Duties – CTLT

June isn't supposed to be a good month for the S&P 500. But it was — especially for investors who chose wisely.

Six Stocks Turn $10,000 Into $63,503 In Six Months

Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.

Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL

Difficulties at the contract manufacturer's site were apparently the reason for a drug's rejection by the FDA. That drug, a more potent form of eye medication Eylea, is made by biotech Regeneron Pharmaceuticals.

Why Catalent Stock Flopped Today

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Catalent, Inc. (NYSE: CTLT) on behalf of long-term stockholders following a class action complaint that was filed against Catalent on February 28, 2023 with a Class Period from August 30, 2021 to October 31, 2022. Our investigation concerns whether the board of directors of Catalent have breached their fiduciary duties to the company. Accordi.

CATALENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Catalent, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

News for Catalent Stock (CTLT)